IMVT Immunovant, Inc.: institutional ownership and insider trading
242 funds reported holding $4.59B of Immunovant, Inc. in their latest 13F filings; in Q2 2026 funds net sold $36.1M, with 36 new positions and 24 funds selling out; over the last 12 months insiders bought $350M and sold $16.3M on the open market.
Famous investors holding IMVT
- David Einhorn (Greenlight Capital): $3.60M, 0.1% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $28.0M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $47.8M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $12.7M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $11.0M, 0.0% of the portfolio
Largest institutional holders of IMVT
- FMR LLC — $624M
- Deep Track Capital, LP — $360M
- BlackRock, Inc. (BLK) — $277M
- FARALLON CAPITAL MANAGEMENT, L.L.C. — $224M
- BAKER BROS. ADVISORS LP — $209M
- VANGUARD GROUP INC — $198M
- STATE STREET CORP (STT, STT-PG) — $178M
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $175M
- TCG Crossover Management, LLC — $172M
- Two Seas Capital LP — $156M
Recent IMVT insider trades
- Oct 21, 2026: Stout Jay S sold 2,595 shares ($75.1K)
- Oct 7, 2026: Stout Jay S sold 3,809 shares ($122K)
- Oct 7, 2026: Gloria Melanie sold 2,241 shares ($71.8K)
- Oct 7, 2026: Van Tuyl Christopher sold 1,327 shares ($42.5K)
5%+ owners
- Roivant Sciences Ltd.: 55.9% (Schedule 13D/A, filed Dec 12, 2025)
- FMR LLC: 8.4% (Schedule 13G/A, filed Nov 5, 2025)